PT  - JOURNAL ARTICLE
AU  - Johansson, Martina
TI  - Insulin Resistance and Metabolic Comorbidities in Alzheimer’s Disease
AID  - 10.1101/2021.04.23.21255980
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.23.21255980
4099  - http://medrxiv.org/content/early/2021/04/25/2021.04.23.21255980.short
4100  - http://medrxiv.org/content/early/2021/04/25/2021.04.23.21255980.full
AB  - Alzheimer’s disease affects 50 million people worldwide and just like any modern lifestyle disease, it is steadily increasing. Unfortunately, a cure has not yet been found, despite decades of research. The pathophysiology of Alzheimer’s disease is extraordinarily complex and involves many different factors. Despite it being a protein misfolding disease, a lot of evidence currently point to insulin resistance, impaired glucose metabolism and comorbidities with other metabolic disorders such as obesity, elevated blood lipids, and non-alcoholic fatty liver disease, as a potential root cause. Genetics aside, it seems like poor metabolic functioning affects the brain and central nervous system a great deal: affecting mood, behaviour, and cognitive performance. Even mood disorders are interlinked with metabolic disorders and increase the risk for Alzheimer’s disease later in life. This is a summary of objectively chosen original research articles, published between 2011-2021 and with insulin resistance as the main objective for cognitive impairment and Alzheimer’s disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/AADAlzheimer’s DiseaseAβAmyloid betaAPPAmyloid beta precursor proteinCBFCerebrospinal blood flowCSFCerebrospinal spinal fluidCICognitive impairmentHPAHypothalamus, Pituitary, AdrenalHOMA-IRHomeostatic model for insulin resistanceIGF-1Insulin growth factor 1IRInsulin resistanceMCIMajor cognitive impairmentMDDMajor depressive disorderNAFLDNon-alcoholic fatty liver diseaseSSPGSteady-state plasma glucoseT2DMType 2 Diabetes MellitusT1DType 1 DiabetesTNF-αTumor necrosis factor alpha